Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histamine H1 receptor

2

Phosphodiesterase 4

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1993

2

2011

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Upper respiratory allergies

2

Chronic obstructive pulmonary disease

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

2

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Altana

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

SMS_ID

3

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHISTAMINES FOR SYSTEMIC USE

1

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIHISTAMINES FOR SYSTEMIC USE

1

OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antihistamines for systemic use

1

Other systemic drugs for obstructive airway diseases

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Roflumilast

0P6C6ZOP5U

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Phosphodiesterase 4

Conditions:

Chronic obstructive pulmonary disease

Roflumilast is a specific phosphodiesterase type (4PDE4) inhibitor indicated for use as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

LORATADINE

7AJO3BO7QN

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Upper respiratory allergies

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system...

depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

LORATADINE HYDROCHLORIDE

RTQ46SZY8H

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Upper respiratory allergies

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system...

depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1